Development based in Switzerland

3 promising

reverse genetics

(VIRUFLEX™) strategies

Next Generation Live-Attenuated SARS-CoV-2 Vaccines

Reverse Genetics (VIRUFLEX™)

and Genotype-to-Phenotype Platform

The reverse genetics platform allows the engineering of viral genomes followed by rapid and efficient recovery of cloned, modified viruses.

Since 2020, our laboratories generated >250 different SARS-CoV-2 clones.

Attenuating mutations are rationally designed and introduced in a targeted and controlled manner.

This platform differentiates our technology from the ancestral, uncontrolled, time-consuming processes needed to generate attenuated vaccines.

The characteristics of our vaccines, as well as their pre-clinical safety, immunogenicity and efficacy are assessed in primary airway cell cultures and well- established animal models.

Live-attenuated virus vaccines through
3 innovative reverse genetics engineering strategies

Our three products have achieved significant milestones:

RVX-sCPD9 has reached a significant milestone asit is now in the GMP-manufacturing phase and preparing for the preclinical GLP-Toxicology study following phase 1/2 clinical development.

RVX-OTS228 is making significant progress as it is currently in the preparation stage for GMP manufacturing.

RVX-13 has shown promising results in animal studies and is currently in the final stages of preclinical proof-of-concept development.


RVX-sCPD9: Codon Pair Deoptimization

  1. Viral genetic modification to reduce translation efficiency using synonymous mutations
  2. Developed in collaboration with Freie Universität Berlin and Friedrich Loeffler Institut for Animal Health, Germany


RVX-OTS: One-to-Stop Codon Modification

  1. Genetic alteration changing a codon to a stop codon, resulting in premature termination of protein synthesis
  2. Developed in collaboration with the University of Bern, Switzerland


RVX-13: Single Cycle Virus or Replication Incompetent SARS-CoV-2 Virus

  1. Modified SAR-CoV-2 unable to complete full life cycle but useful for antigen expression
  2. Developed in collaboration with the University of Basel, Switzerland
Significant benefits and encouraging milestones

Attenuated viruses have been successfully used for measles, mumps, rubella (MMR combined vaccine), rotavirus, smallpox, chickenpox (varicella), and yellow fever.

These vaccines provide broad and long-lasting immunity, effectively preventing both initial and repeat infections.

By mimicking the natural route of virus entry, these vaccines stimulate an adequate immune response in the upper respiratory tract (mucosal immunity).

The use of attenuated SARS-CoV-2 virus vaccines can reduce the risk of developing long-COVID symptoms and also helps to prevent transmission of the virus to contacts.

These vaccines are well-tolerated and can be administered without needles via an intranasal route.

Preliminary data suggest that attenuated SARS-CoV-2 virus vaccines may be effective as booster shots for the majority of the population.

The stable vaccine formulation does not require cold storage, facilitating transport and distribution.

The manufacturing and scale-up processes for attenuated virus vaccines have been established and refined.

The recent equity deal between a Swiss canton and RocketVax marks an important milestone in the history of Switzerland, as it is the first of its kind.

Beyond SARS-CoV-2:

RocketVax's innovative platform for pandemic readiness

RocketVax is an innovative platform for synthetic genomics that focuses on infectious diseases, pandemic readiness, cancer, and multiple sclerosis beyond SARS-CoV-2. Their approach involves using attenuated viruses and nasal delivery to address a wide range of respiratory illnesses, while also leveraging their expertise to combat future unknown diseases, or "Disease X”.